Ohta K, Kim S, Wanibuchi H, Ganten D, Iwao H
Department of Pharmacology, Osaka City University Medical School, Japan.
Circulation. 1996 Aug 15;94(4):785-91. doi: 10.1161/01.cir.94.4.785.
The transgenic rat TGR(mRen2)27, carrying the mouse Ren-2 gene, is a new model to elucidate the role of the local renin-angiotensin system in vivo. However, the role of the local renin-angiotensin system in the heart remains to be determined in TGR(mRen2)27.
TGR(mRen2)27 were treated with various antihypertensive drugs for 6 weeks to examine the effects on cardiac hypertrophy and gene expression. Cardiac mRNAs were examined by Northern blot analysis. In TGR(mRen2)27, left ventricular hypertrophy was associated with a decrease in alpha-myosin heavy chain expression of 31% and an increase in skeletal alpha-actin and atrial natriuretic polypeptide expression by 2.6- and 21-fold, respectively (P < .05), thereby showing the shift of myocardium to a fetal phenotype. Furthermore, cardiac collagen and laminin expressions were increased in TGR(mRen2)27 (P < .05), suggesting the occurrence of cardiac remodeling. Although treatment of TGR(mRen2)27 with a high dose of TCV-116 (angiotensin AT1 receptor antagonist) or manidipine (calcium antagonist) combined with atenolol (beta 1-adrenergic receptor blocker) completely normalized blood pressure, TCV-116 regressed cardiac hypertrophy and suppressed the changes in cardiac mRNA levels of TGR(mRen2)27 much more potently than manidipine with atenolol. Furthermore, the inhibitory effects of a low dose of TCV-116 on cardiac hypertrophy and altered gene expressions of TGR(mRen2)27 were greater than those of doxazosin (alpha 1-adrenergic receptor blocker) combined with atenolol, despite their similar hypotensive effects.
Our present observations provide evidence that the cardiac renin-angiotensin system in TGR(mRen2)27 is responsible for cardiac hypertrophy, phenotypic modulation, and remodeling.
携带小鼠Ren - 2基因的转基因大鼠TGR(mRen2)27是一种用于阐明体内局部肾素 - 血管紧张素系统作用的新模型。然而,局部肾素 - 血管紧张素系统在心脏中的作用在TGR(mRen2)27中仍有待确定。
用各种抗高血压药物对TGR(mRen2)27进行6周治疗,以检查对心脏肥大和基因表达的影响。通过Northern印迹分析检测心脏mRNA。在TGR(mRen2)27中,左心室肥大与α - 肌球蛋白重链表达降低31%以及骨骼肌α - 肌动蛋白和心钠素表达分别增加2.6倍和21倍相关(P < 0.05),从而显示心肌向胎儿表型转变。此外,TGR(mRen2)27中心脏胶原蛋白和层粘连蛋白表达增加(P < 0.05),提示心脏重塑的发生。尽管用高剂量的TCV - 116(血管紧张素AT1受体拮抗剂)或马尼地平(钙拮抗剂)联合阿替洛尔(β1 - 肾上腺素能受体阻滞剂)治疗TGR(mRen2)27可使血压完全正常化,但TCV - 116比马尼地平联合阿替洛尔更有效地减轻心脏肥大并抑制TGR(mRen2)27心脏mRNA水平的变化。此外,低剂量的TCV - 116对TGR(mRen2)27心脏肥大和基因表达改变的抑制作用大于多沙唑嗪(α1 - 肾上腺素能受体阻滞剂)联合阿替洛尔,尽管它们的降压效果相似。
我们目前的观察结果提供了证据,表明TGR(mRen2)27中的心脏肾素 - 血管紧张素系统与心脏肥大、表型调节和重塑有关。